Question

Difficulty: Very hardInfectious Diseases

An elderly male patient, aged 72, comes to the clinic reporting a four-week history of profound fatigue, night sweats, and unintentional weight loss. He notes that these symptoms began roughly two weeks after he underwent a transurethral resection of the prostate for benign prostatic hyperplasia. His temperature in the clinic is 38.2°C (100.8°F), blood pressure is 134/68 mm Hg, and pulse is 96/min. Cardiovascular auscultation reveals a new early diastolic decrescendo murmur best heard at the left third intercostal space. Physical examination also demonstrates nontender, erythematous macules on the palms and soles. Transesophageal echocardiography confirms a mobile, 1.1-cm vegetation on the right coronary cusp of the aortic valve. Two days later, all three sets of blood cultures are positive for *Enterococcus faecalis*. Antimicrobial susceptibility testing indicates that the isolate is susceptible to ampicillin and vancomycin. However, high-level resistance to both gentamicin and streptomycin is detected. Renal function is within normal limits. Which of the following is the most appropriate definitive intravenous antibiotic regimen for this patient?

  1. Ampicillin and ceftriaxoneAnswer
  2. B
    Ampicillin and gentamicin
  3. C
    Vancomycin and gentamicin
  4. D
    Daptomycin monotherapy
  5. E
    Ampicillin monotherapy

Answer

Ampicillin and ceftriaxone
The correct answer is ampicillin and ceftriaxone. Enterococcal endocarditis requires bactericidal therapy, but beta-lactams alone are only bacteriostatic against these organisms. While the classic synergistic regimen is ampicillin plus gentamicin, the presence of high-level aminoglycoside resistance (HLAR) abolishes this synergy. In cases of HLAR, the standard of care is a dual beta-lactam regimen of ampicillin and ceftriaxone. Although enterococci are intrinsically resistant to cephalosporins, ceftriaxone works synergistically with ampicillin by saturating complementary penicillin-binding proteins (PBPs), resulting in highly effective bactericidal activity while avoiding aminoglycoside toxicity.

Step-by-Step Solution

1
Identify the primary clinical syndrome and causative organism.
The patient has subacute infective endocarditis (new murmur, Janeway lesions, positive echo) caused by Enterococcus faecalis, likely seeded during his recent genitourinary surgery.
Establishing the diagnosis and pathogen is the first prerequisite for tailoring antimicrobial therapy.
2
Determine the pharmacological requirements for treating this specific infection.
Endocarditis requires bactericidal therapy to sterilize the heart valve. Because cell-wall active agents (like ampicillin) are only bacteriostatic against Enterococcus, a second agent is needed to achieve bactericidal synergy.
Monotherapy with beta-lactams is insufficient for curing enterococcal endocarditis.
3
Analyze the susceptibility data provided.
The isolate has high-level aminoglycoside resistance (HLAR). This means that adding an aminoglycoside (like gentamicin or streptomycin) will not result in bactericidal synergy and will only cause toxicity.
Identifying HLAR explicitly rules out the traditional ampicillin plus gentamicin regimen.
4
Select the appropriate alternative synergistic regimen.
The combination of ampicillin and ceftriaxone is selected. This dual beta-lactam therapy provides bactericidal synergy against E. faecalis.
Ceftriaxone saturates peripheral penicillin-binding proteins (PBP2, PBP3), while ampicillin saturates the remaining PBPs (PBP4, PBP5), working together to effectively kill the bacteria without requiring an aminoglycoside.

Key Concept

Management of Enterococcus faecalis infective endocarditis with high-level aminoglycoside resistance (HLAR) requires dual beta-lactam therapy (ampicillin and ceftriaxone) to achieve bactericidal synergy.
Estimated Time:2m 0s
Rate this question